Fexofenadine Hydrochloride is a non-sedating H1 antihistamine indicated for seasonal allergic rhinitis and chronic idiopathic urticaria. We supply it to US manufacturers of tablets, orally disintegrating tablets and oral suspension.
Data from PubChem (CID 63002) and FDA’s substance registry
CAS number
153439-40-8
Molecular formula
C32H40ClNO4
Molecular weight
538.1g/mol
FDA UNII
IUPAC name
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid;hydrochloride
InChIKey
RRJFVPUCXDGFJB-UHFFFAOYSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Exists in several polymorphic and hydrated forms. State the form you developed with.
On the US market
- Reference product
- AllegraNDA 020625
- Approved ANDAs
- 15 with a marketed product
- Approved forms and strengths
- Tablet 30 mg, 60 mg, 180 mg
- Oral suspension 30 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com